Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
-
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
-
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
-
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
-
Conduit Pharmaceuticals Announces Leadership Changes
-
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
-
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
-
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
-
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
-
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904